USNA Usana Health Sciences Inc

  1. Stocks
  2. Consumer Defensive
  3. NYSE: USNA

Price (delayed)

$13.55

Market cap

$250.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.2

Enterprise value

$81.8M

?
Relative Growth: Rel. Growth: 4
Relative Strength: Rel. Strength: 7
Relative Valuation: Rel. Valuation: 66
Relative Profitability: Rel. Profitability: 40

USANA has been providing premium-quality nutrition and lifestyle products for more than 30 years. From its award-winning supplements manufactured in its FDA-registered facility to its cutting-edge Celavive® skincare and healthy ...

Highlights
USNA's debt has plunged by 100% from the previous quarter
The quick ratio has grown by 31% YoY and by 11% from the previous quarter
The EPS has plunged by 167% YoY
USNA's net income has dropped by 165% year-on-year
Sector: Consumer Defensive
Industry: Packaged Foods
Website: http://www.usana.com
Peers: NATR NUS MTEX IPAR

Key stats

What are the main financial stats of USNA

USNA stock price

How has the Usana Health Sciences stock price performed over time
Intraday
2.81%
1 week
1.35%
1 month
-38.74%
1 year
-55.76%
YTD
-30.97%
QTD
-36.53%

Financial performance

How have Usana Health Sciences's revenue and profit performed over time
Revenue
$913.36M
Gross profit
$707.36M
Operating income
-$1.08M
Net income
-$22.16M
Gross margin
77.4%
Net margin
-2.4%
USNA's net income has dropped by 165% year-on-year
USNA's net margin has plunged by 163% YoY
Usana Health Sciences's operating margin has shrunk by 103% QoQ and by 102% YoY
The operating income has dropped by 103% since the previous quarter and by 102% year-on-year

Price vs fundamentals

How does USNA's price correlate with its fundamentals

Growth

What is Usana Health Sciences's growth rate over time

Valuation

What is Usana Health Sciences stock price valuation
USNA P/E details
P/E
N/A
P/B
0.48
P/S
0.27
EV/EBIT
8.15
EV/EBITDA
1.67
EV/Sales
0.09
The EPS has plunged by 167% YoY
USNA's P/B is 77% below its 5-year quarterly average of 2.1 and 31% below its last 4 quarters average of 0.7
The company's equity fell by 3.2% QoQ
USNA's price to sales (P/S) is 73% less than its 5-year quarterly average of 1.0 and 33% less than its last 4 quarters average of 0.4

Efficiency

How efficient is Usana Health Sciences business performance
The ROE has plunged by 166% YoY
Usana Health Sciences's ROA has plunged by 165% YoY
The company's return on invested capital has shrunk by 87% YoY and by 76% QoQ
The ROS has plunged by 85% YoY and by 75% from the previous quarter

Dividends

What is USNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for USNA.

Financial health

How did Usana Health Sciences financials performed over time
The quick ratio has grown by 31% YoY and by 11% from the previous quarter
The current ratio has increased by 24% YoY and by 6% from the previous quarter
USNA's debt is 100% less than its equity
USNA's debt has plunged by 100% from the previous quarter
The debt to equity has plunged by 100% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.